Megan Sanders, Chief Executive Officer at Thoracic Oncology Group of Australasia, shared on LinkedIn:
“And that’s a wrap!
Expertly chaired by Dr Kortnye Smith, TOGA’s post-ESMO International Conference Highlights showcased some exciting advances in lung cancer research and treatment, followed by an excellent Q and A with insightful questions and discussion about the implications for clinical practice.
We even had a bonus rundown of the melanoma cancer vaccine study and what its findings might mean for the future of lung cancer treatment.
A huge thank you to all our presenters, everyone who joined the discussion, and our sponsor, Pfizer, for supporting this event.
Keep an eye on our YouTube channel over the next few days to catch the highlights, featuring tarlatamab, sacituzumab tirumotecan (sac-TMT), KRAS G12C inhibitors, savolitinib and ongoing research to optimise the delivery of immune checkpoint inhibitors.
You can also read: LungÕ 2026: Global Experts Examine the Changing Landscape of Lung Cancer Care
